IGF-1与异型内类固醇激素注射治疗突发性聋合并2型糖尿病的新进展

陈英; 裴婷; 孙媛; 江俊; 张海利

doi:10.13201/j.issn.2096-7993.2020.06.021

IGF-1与异型内类固醇激素注射治疗突发性聋合并2型糖尿病的新进展

- 1.
  山西医科大学第一临床医学院(太原，030001)
- 2.
  山西医科大学第一医院耳鼻咽喉头颈外科

详细信息

通讯作者: 张海利，E-mail：790261205@qq.com

^Δ审校者

中图分类号: R764.43

收稿日期: 2019-05-26

刊出日期: 2020-06-05

New progress of IGF-1 and allosteroid injection in the treatment of sudden deafness complicated with type 2 diabetes

More Information

Corresponding author: ZHANG Haili, E-mail: 790261205@qq.com

Received Date: 26 May 2019

Publish Date: 05 June 2020

摘要

- 听力丧失，突发性 /
- 2型糖尿病 /
- 糖皮质激素 /
- 外用胰岛素样生长因子
Abstract: Glucocorticoids are a recognized treatment for sudden deafness, and there has always been a contradiction between the control of blood glucose levels and the use of glucocorticoids. The systemic use of hormones may lead to a series of adverse events, which are dose-dependent. High doses can induce an increase in blood sugar, especially for patients with type 2 diabetes, which can aggravate their condition or cause complications. The systemic application of glucocorticoids has been largely replaced by local glucocorticoids treatment. Topical insulin-like growth factor (IGF-1) is used without increasing blood sugar, thus avoiding the possible complications. The author intends to compare the local IGF-1 treatment and local glucocorticoid treatment to systemic therapy. The efficacy of local IGF-1 therapy in treating corticosteroid-refractory sudden sensorineural hearing loss combined with type 2 diabetes is reviewed.
- sudden deafness /
- type 2 diabetes /
- glucocorticoid /
- topical insulin-like growth factor

HTML全文

参考文献(37)

[1]	Chandrasekhar Sujana S, Tsai Do Betty S, Schwartz Seth R, et al. Clinical Practice Guideline: Sudden Hearing Loss(Update)[J]. Otolaryngol Head Neck Surg, 2019, 161(1S): S1-S45.
[2]	American Diabetes Association. Standards of Medical Care in Diabetes-2019[J]. Diabetes Care, 2019, 42(Suppl 1): S1-S193.
[3]	Koçak HE, Filiz Acıpayam AŞ, Acıpayam H et al. Microvascular dysfunction affects the development and prognosis of sudden idiopathic hearing loss[J]. Clin Otolaryngol, 2017, 42(3): 602-607. doi: 10.1111/coa.12780
[4]	Fukushima H, Cureoglu S, Schachern PA, et al. Effects of type 2 diabetes mellitus on cochlear structure in humans[J]. Arch Otolaryngol Head Neck Surg, 2006, 132(9): 934-938. doi: 10.1001/archotol.132.9.934
[5]	Garefa Callejo FJ, Orts Alborcfh MH, Morant Ventura A, et al. Neurosensory sudden deafness, blood hyperviscosity syndrome, and diabetes mellitus[J]. Acta Otorrinolatingol Esp, 2002, 53(3): 221-224. doi: 10.1016/S0001-6519(02)78304-0
[6]	Orita S, Fukushima K, Orita Y, et al. Sudden hearing impairment combined with diabetes mellitus or hyperlipidemia[J]. Eur Arch Otorhinolaryngol, 2007, 264(4): 359-362. doi: 10.1007/s00405-006-0196-6
[7]	Aimoni C, Bianchini C, Borin M, et al. Diabetes, cardiovascular risk factors and idiopathic sudden sensorineural hearing loss: a case-control study[J]. Audiol Neurootol, 2010, 15(2): 111-115. doi: 10.1159/000231636
[8]	Ryu OH, Choi MG, Park CH, et al. Hyperglycemia as a potential prognostic factor of idiopathic suddensensorineural hearing loss[J]. Otolaryngol Head Neck Surg, 2014, 150(5): 853-858. doi: 10.1177/0194599814521012
[9]	Stachler Robert J, Chandrasekhar Sujana S, Archer Sanford M, et al. Clinical practice guideline: sudden hearing loss[J]. Otolaryngol Head Neck Surg, 2012, 146(1S): S1-35.
[10]	Rohrmeier C, Koemm N, Babilas P, et al. Sudden sensorineural hearing loss: systemic steroid therapy and the risk of glucocorticoid-induced hyperglycemia[J]. Eur Arch Otorhinolaryngol, 2013, 270(4): 1255-1261. doi: 10.1007/s00405-012-2134-0
[11]	Yu GH, Choi YJ, Jung HJ, et al. A comparison of single-dose and multiple divided daily-dose oral steroids for suddensensorineural hearing loss[J]. Braz J Otorhinolaryngol, 2019, 85(6): 733-738. doi: 10.1016/j.bjorl.2018.06.001
[12]	Silverstein H, Choo D, Rosenberg SI, et al. Intratympanic steroid treatment of inner ear disease and tinnitus(preliminary report)[J]. Ear Nose Throat J, 1996, 75(8): 468-471, 474, 476. doi: 10.1177/014556139607500806
[13]	Wang Y, Han L, Diao T, et al. A comparison of systemic and local dexamethasone administration: From perilymph/cochleaconcentration to cochlear distribution[J]. Hear Res, 2018, 370: 1-10. doi: 10.1016/j.heares.2018.09.002
[14]	Lee JJ, Jang JH, Choo OS, et al. Steroid intracochlear distribution differs by administration method: Systemic versusintratympanic injection[J]. Laryngoscope, 2018, 128(1): 189-194. doi: 10.1002/lary.26562
[15]	Wilson SM, Shen P, Rider CF, et al. Selective prostacyclin receptor agonism augments glucocorticoid-induced gene expression in human bronchial epithelial cells[J]. J Immunol, 2009, 183(10): 6788-6799. doi: 10.4049/jimmunol.0902738
[16]	陈爱平, 王海波. 耳后注射糖皮质激素治疗突发性聋的研究进展[J]. 临床耳鼻咽喉头颈外科杂志, 2016, 30(19): 1572-1575. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH201619021.htm
[17]	Rauch SD, Halpin CF, Antonelli PJ, et al. Oral VS intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial[J]. JAMA, 2011, 305(20): 2071-2079. doi: 10.1001/jama.2011.679
[18]	王海茹, 王海涛, 郝玲. 耳后与全身应用糖皮质激素治疗突发性耳聋系统评价与Meta分析[J]. 中华耳科学杂志, 2018, 16(5): 669-675. doi: 10.3969/j.issn.1672-2922.2018.05.015
[19]	李代波, 周松, 徐文均. 鼓室注射地塞米松与耳后骨膜下注射甲强龙治疗突发性聋的疗效及不良反应对比[J]. 临床耳鼻咽喉头颈外科杂志, 2017;31(16): 1265-1268. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH201716012.htm
[20]	Lai D, Zhao F, Jalal N. Intratympanic glucocorticosteroid therapy for idiopathic sudden hearing loss: Meta-analysis of randomized controlled trials[J]. Medicine(Baltimore), 2017, 96(50): e8955.
[21]	Halmos T, Suba I. The physiological role of growth hormone and insulin-like growth factors[J]. Orv Hetil, 2019, 160(45): 1774-1783. doi: 10.1556/650.2019.31507
[22]	Hu F, Liu F. Targeting tissue-specific metabolic signaling pathways in aging: the promise and limitations[J]. Protein Cell, 2014, 5(1): 21-35. doi: 10.1007/s13238-013-0002-3
[23]	Murillo-Cuesta S, Rodríguez-de la Rosa L, Cediel R, et al. The role of insulin-like growth factor-I in the physiopathology of hearing[J]. Front Mol Neurosci, 2011, 4: 11-11.
[24]	Yamahara K, Nakagawa T, Ito J, et al. Netrin 1 mediates protective effects exerted by insulin-like growth factor 1 on cochlear hair cells[J]. Neuropharmacology, 2017, 119: 26-39. doi: 10.1016/j.neuropharm.2017.03.032
[25]	Cediel R, Riquelme R, Contreras J, et al. Sensorineural hearing loss in insulin-like growth factor I-null mice: a new model of humandeafness[J]. Eur J Neurosci, 2006, 23(2): 587-590. doi: 10.1111/j.1460-9568.2005.04584.x
[26]	Lee KY, Nakagawa T, Okano T, et al. Novel therapy for hearing loss: delivery of insulin-like growth factor 1 to the cochlea using gelatin hydrogel[J]. Otol Neurotol, 2007, 28(7): 976-981. doi: 10.1097/MAO.0b013e31811f40db
[27]	Fujiwara T, Hato N, Nakagawa T, et al. Insulin-like growth factor 1 treatment via hydrogels rescues cochlear hair cells from ischemicinjury[J]. Neuroreport, 2008, 19(16): 1585-1588. doi: 10.1097/WNR.0b013e328311ca4b
[28]	Hayashi Y, Yamamoto N, Nakagawa T, et al. Insulin-like growth factor 1 inhibits hair cell apoptosis and promotes the cell cycle of supportingcells by activating different downstream cascades after pharmacological hair cell injury in neonatal mice[J]. Mol Cell Neurosci, 2013, 56: 29-38. doi: 10.1016/j.mcn.2013.03.003
[29]	Yamahara K, Yamamoto N, Nakagawa T, et al. Insulin-like growth factor 1: A novel treatment for the protection or regeneration of cochlear haircells[J]. Hear Res, 2015, 330(Pt A): 2-9.
[30]	Filus A, Zdrojewicz Z. [Insulin-like growth factor-1(IGF-1)-structure and the role in the human body] [J]. Pediatr Endocrinol Diabetes Metab, 2015, 20(4): 161-169.
[31]	Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes[J]. Endocrinol Metab Clin North Am, 2012, 41(2): 425-443. doi: 10.1016/j.ecl.2012.04.017
[32]	Nakagawa T, Sakamoto T, Hiraumi H, et al. Topical insulin-like growth factor 1 treatment using gelatin hydrogels for glucocorticoid-resistant sudden sensorineural hearing loss: a prospective clinical trial[J]. BMC Med, 2010, 8: 76-76. doi: 10.1186/1741-7015-8-76
[33]	Nakagawa T, Kumakawa K, Usami S, et al. A randomized controlled clinical trial of topical insulin-like growth factor-1 therapy for sudden deafness refractory to systemic corticosteroidtreatment[J]. BMC Med, 2014, 12: 219-219. doi: 10.1186/s12916-014-0219-x
[34]	Yamamoto N, Nakagawa T, Ito J. Application of insulin-like growth factor-1 in the treatment of inner eardisorders[J]. Front Pharmacol, 2014, 5: 208-208.
[35]	Nakagawa T, Ogino-Nishimura E, Hiraumi H, et al. Audiometric outcomes of topical IGF1 treatment for sudden deafnessrefractory to systemic steroids[J]. Otol Neurotol, 2012, 33(6): 941-96. doi: 10.1097/MAO.0b013e31825f251a
[36]	Nakagawa T, Yamamoto M, Kumakawa K, et al. Prognostic impact of salvage treatment on hearing recovery in patients with sudden sensorineural hearing loss refractory to systemiccorticosteroids: A retrospective observational study[J]. Auris Nasus Larynx, 2016, 43(5): 489-494. doi: 10.1016/j.anl.2015.12.004
[37]	Amarillo E, Hernando M, Eisenberg G, et al. Efficacy of intratympanic corticosteroid as a salvage treatment in idiopathic sudden sensorineural hearing loss[J]. Acta Otorrinolaringol Esp, 2019, 70(4): 207-214. doi: 10.1016/j.otorri.2018.04.009